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[GFR] ≥ 60 ml/min/1.73 m , n = 393) versus moderate-to-severely
impaired renal function (GFR < 60 ml/min/1.73 m2, n = 206) were
compared and the difference between the two curves was  not sta-
tistically signiﬁcant (p = 0.34) (Fig. 1) [8].eywords:
atriuretic peptide
-type natriuretic peptide
T-proBNP
eart failure
enal failure
B-type natriuretic peptide (BNP) was ﬁrst identiﬁed in porcine
rain in 1988 and originally was termed brain natriuretic pep-
ide. Subsequently, it was detected in ventricular cardiomyocytes
nd the ventricular myocardium was later recognized as the major
ource of circulating BNP. The main stimulus for increased BNP
ynthesis and secretion is wall stress and BNP is synthesized as
 proBNP comprising 108 amino acids. Upon release into the cir-
ulation, it is cleaved in equal proportion into the biologically
ctive 32 acid BNP and the biologically inactive 76 amino acid
-terminal fragment, NT-proBNP. BNP relaxes vascular smooth
uscle, dilates arteries and veins, lowers blood pressure and
entricular preload, and inhibits sympathetic activity and the
enin–angiotensin–aldosterone system. It also increases glomeru-
ar ﬁltration and inhibits sodium reabsorption by the kidney,
romoting natriuresis and diuresis [1,2]. BNP is mainly cleared
rom plasma by binding to the natriuretic peptide receptor type
 (NPR-C) and through proteolysis by neutral endopeptidases. In
ontrast, NT-proBNP is cleared by renal clearance. This ﬁnding led
o the incorrect hypothesis that NT-proBNP is dependent on renal
unction whereas BNP is not dependent on renal function. How-
ver, studies have shown correlation coefﬁcients between BNP and
stimated glomerular ﬁltration rate (eGFR) [3,4].
BNP and NT-proBNP are mostly used as diagnostic biomark-
rs of acute heart failure (HF). The contributions of blood BNP or
T-proBNP measurements in the initial evaluation of patients pre-
enting with acute HF have been conﬁrmed. In the multicenter
reathing-Not-Properly Study, the use of a 100 pg/ml BNP (Triage,
iosite, San Diego, CA, USA) concentration as a diagnostic “cut-off”,
dentiﬁed HF as the cause of acute dyspnea with a 90% sensitivity,
6% speciﬁcity, and an 83% diagnostic accuracy, in 1586 patients
resenting to the emergency department, which was  superior to clinical assessment alone [5]. The similar contributions made by
he measurements of NT-proBNP were conﬁrmed in the ProBNP
nvestigation of Dyspnea in the Emergency Department (PRIDE)
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ttp://dx.doi.org/10.1016/j.jjcc.2013.01.013Study, in 600 patients presenting with acute dyspnea. NT-proBNP
concentrations >450 pg/ml at <50 years of age, and >900 pg/ml
at ≥50 years of age, were highly sensitive and speciﬁc for the
diagnosis of acute HF, while <300 pg/ml was  optimal to exclude
acute HF, with a negative predictive value of 99% [6]. From
these observations, the National Academy of Clinical Biochemistry
(NACB) laboratory medicine practice guidelines stated that “the use
of BNP or NT-proBNP testing in an acute setting to rule out or to conﬁrm
the diagnosis of heart failure among patients with ambiguous signs and
symptoms”, and was assigned a class I, level of evidence A [7]. From
the PRIDE study, the use of NT-proBNP is valuable for the evalu-
ation of the dyspneic patient, irrespective of renal function. With
receiver-operating characteristic (ROC) curves, the performance of
NT-proBNP for the diagnosis of acute HF in breathless subjects
with normal-to-mild renal insufﬁciency (glomerular ﬁltration rate
2Fig. 1. Receiver-operating characteristic curves comparing the performance of
amino-terminal pro-brain natriuretic peptide for the diagnosis of acute conges-
tive  heart failure in breathless subjects with normal-to-mild renal insufﬁciency
(glomerular ﬁltration rate [GFR] ≥ 60 ml/min/1.73 m2, n = 393) versus moderate-
to-severely impaired renal function (GFR < 60 ml/min/1.73 m2, n = 206) [8]. The
difference between the two curves was not statistically signiﬁcant (p = 0.34).
vier Ltd. All rights reserved.
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BNP and NT-proBNP are also used as prognostic markers in
atients with HF. It is particularly noteworthy that, by multiple
ariable analysis, in the Valsartan Heart Failure Trial (Val-HeFT),
orepinephrine, BNP, aldosterone, plasma renin activity, big
ndothelin (ET)-1, and ET-1 were assayed at baseline in 4300
atients. By multiple variable analysis, BNP was most closely
orrelated with mortality [9]. A substudy of the Carvedilol Prospec-
ive Randomized Cumulative Survival (COPERNICUS) examined the
rognostic value of NT-proBNP in a large population of patients pre-
enting with severe chronic HF [10]. Therefore, NACB laboratory
edicine practice guidelines state that “Blood BNP or NT-proBNP
esting can provide a useful addition to clinical assessment in selected
ituations when additional risk stratiﬁcation is required” and assigned
t a class IIa, Evidence level A [7].
In this issue, Horii reports that the area under the receiving
perating characteristic curve (AUC) of BNP and NT-proBNP for
ortality and cardiovascular events were similar for chronic kid-
ey disease (CKD) stage 1–3. However, for CKD stage 4–5, AUC of
T-proBNP was higher than AUC of BNP. It was  concluded that
T-proBNP is a superior prognostic marker to BNP for CKD stage
–5. Calculated optimal cutoff values of BNP for all-cause death
ere 87.0 pg/ml in patients with an eGFR ≥ 30 ml/min/1.73 m2, and
14.5 pg/ml in patients with an eGFR < 30 ml/min/1.73 m2, so the
ptimal cutoff values differed by 30%. However, the optimal cutoff
alues of NT-pro BNP for all-cause death were 258 pg/ml in patients
ith an eGFR ≥ 30 ml/min/1.73 m2, and 5809 pg/ml in patients with
n eGFR < 30 ml/min/1.73 m2. From a clinical point of view, it was
oncluded that it should be noted that the optimal cutoff of NT-
roBNP varied quite widely based on renal function [11].
In a subanalysis of 720 patients presenting with acute decom-
ensated HF from the International Collaborative on NT-proBNP
ICON) study, NT-proBNP level was predictive of 60-day outcome
n the setting of impaired renal function. Both an eGFR < 60 ml/min
er 1.73 m2 and an NT-proBNP level above the median (4647 ng/l)
redicted a poor outcome. Intriguingly, these investigators identi-
ed that it was the combination of both that carried the greatest
isk (Fig. 2) [12]. Another study has also compared BNP and NT-
roBNP for all-cause mortality in emergency department patients
resenting with dyspnea and an eGFR < 60 ml/min per 1.73 m2.
T-proBNP levels were superior predictors of 1-year mortality
ig. 2. Survival curves of heart failure subjects in ICON (International Collaborative
n  NT-proBNP) as a function of glomerular ﬁltration rate (GFR) and amino-
erminal pro-brain natriuretic peptide (NT-proBNP) concentration on admission
12]. Patients with both an eGFR < 60 ml/min per 1.73 m2 and an NT-proBNP level
bove the median (4647 ng/l) carried the greatest risk.
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after adjustment for comorbidities, renal function, and diagnosis
of decompensated HF [13].
In conclusion, NT-proBNP is as useful as BNP for the prognostic
and diagnostic evaluation of patients with HF irrespective of renal
function. Particularly in patients with severe CKD, NT-proBNP is a
superior prognostic marker than BNP, although the optimal cutoff
of NT-proBNP varied quite widely based on renal function.
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